August 6, 2019 06:37 AM EDT

In draft guidance, NICE fails to back Clovis's PARP inhibitor Rubraca

Natalie Grover

Reporter

Despite the EMA’s endorsement of Clovis’s cancer treatment Rubraca last year, the UK’s cost-effectiveness watchdog NICE has recommended against the adoption of the drug in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In draft guidance, NICE fails to back Clovis's PARP inhibitor Rubraca

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

In draft guid­ance, NICE fails to back Clo­vis's PARP in­hibitor Rubra­ca

Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

In draft guidance, NICE fails to back Clovis's PARP inhibitor Rubraca